Cargando…

Metabolic Vulnerabilities in Multiple Myeloma

SIMPLE SUMMARY: The advent of novel therapeutics has revolutionized the therapeutic scene of multiple myeloma (MM) and improved clinical outcomes significantly. Nonetheless, the disease remains incurable, especially in patients with refractory and relapsed disease. The emerging field of cancer metab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Julia S. L., Chong, Phyllis S. Y., Chng, Wee-Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029117/ https://www.ncbi.nlm.nih.gov/pubmed/35454812 http://dx.doi.org/10.3390/cancers14081905

Ejemplares similares

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

Lipid metabolic vulnerabilities of multiple myeloma
por: Torcasio, Roberta, et al.
Publicado: (2023)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma
por: Wang, Samuel S. Y., et al.
Publicado: (2022)

Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
por: Xiong, Sinan, et al.
Publicado: (2021)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
por: Teoh, Phaik Ju, et al.
Publicado: (2016)

Genomic characterization of functional high-risk multiple myeloma patients
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2022)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
por: Chung, Tae-Hoon, et al.
Publicado: (2013)

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
por: Lim, Su-Lin, et al.
Publicado: (2020)

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
por: Teoh, Phaik Ju, et al.
Publicado: (2020)

Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma
por: Rana, Priyanka S., et al.
Publicado: (2023)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
por: Li, Zhenhai, et al.
Publicado: (2020)

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
por: Wang, Chen, et al.
Publicado: (2020)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells
por: Xie, Zhigang, et al.
Publicado: (2011)

Clonogenic Multiple Myeloma Cells have Shared stemness Signature Associated with Patient Survival
por: Reghunathan, Renji, et al.
Publicado: (2013)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

Metabolic Features of Multiple Myeloma
por: El Arfani, Chaima, et al.
Publicado: (2018)

Metabolic Disorders in Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma
por: Bi, Chonglei, et al.
Publicado: (2015)

Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact
por: Li, Zhenhai, et al.
Publicado: (2019)

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations
por: Lim, Su Lin, et al.
Publicado: (2019)

Metabolic Volume Measurements in Multiple Myeloma
por: Takahashi, Maria Emilia Seren, et al.
Publicado: (2021)

Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2013)

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
por: Murray, David L., et al.
Publicado: (2021)

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
por: Yao, Yao, et al.
Publicado: (2023)

The Sec61 translocon is a therapeutic vulnerability in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2022)

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma
por: Jia, Yunlu, et al.
Publicado: (2021)

Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
por: Jia, Yunlu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4km3rb5ce5ier0ci6p051pgck3